By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Myriad Genetics slumped to a 52-week low earlier today, after the firm's stock was downgraded by investment bank JP Morgan.

Myriad fell to as low as $14.26 before rebounding slightly in the afternoon to $14.75 — still down 6 percent on the day.

JP Morgan downgraded Myriad's stock to "neutral" from "overweight" and cut its price target to $18 from $28.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A fire at a Manchester hospital may have destroyed lab equipment and data, the Guardian reports.

Researchers generate a genetic database from skeletal remains from the 1845 Franklin Expedition to the Arctic, Live Science reports.

Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.

In Science this week: human DNA found in sediments from archeological sites lacking bones, and more.